Q-omics provides the consensus-scored KMT5A profile across patient tissues and cancer cell-line models. KMT5A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, KMT5A is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, KMT5A RNA expression shows 19,641 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and THCA as cancer lineages where KMT5A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KMT5A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KMT5A survival associations across molecular data types. KMT5A RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KMT5A RNA expression–survival associations across cancer types. High KMT5A expression shows unfavorable associations in ACC, LIHC, KICH, KIRC, UVM and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for KMT5A RNA expression.
This table summarizes KMT5A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KMT5A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KMT5A shows lower tumor expression in THCA and higher tumor expression in LIHC, LUSC, HNSC, COAD and KIRP. The THCA box plot shows higher KMT5A RNA expression in normal versus tumor tissue (log2 FC = −0.907, t-test p < 0.001).
This table shows molecular features associated with KMT5A in patient tissues and cancer cell lines. In patient samples, KMT5A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KMT5A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
